Stock futures ticked higher on Wednesday (July 9) as investors assessed the latest tariff signals from President Donald Trump ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Semaglutide is making waves as the powerhouse ingredient in Ozempic and ...

While effective for managing type 2 diabetes and promoting weight loss as a secondary benefit, Ozempic is not suitable for ...

Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.

By Elizabeth Shockman, MPR News acing a massive increase in employee health insurance rates, leaders at Anoka-Hennepin Area Schools last May asked a question out loud: Should the district stop paying ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...